Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer [Yahoo! Finance]
Rani Therapeutics Holdings, Inc. - Class A (RANI)
Company Research
Source: Yahoo! Finance
biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer. “We are thrilled to announce Alireza's promotion to Chief Technical Officer as we enter an exciting era for Rani, highlighted by our collaboration with Chugai and our newly initiated Phase 1 study of RT-114 for the treatment of obesity,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “His technical and operational leadership experience in the medical device and life science industries will be instrumental in scaling our supply chain and manufacturing capabilities as we continue to advance our pipeline.” Prior to the promotion to Chief Technical Officer, Alireza served as Vice President, Technical Operations, where he was responsible for Rani's R&D, manufacturing, and automation teams. In this expanded role, he will continue to lead these core functions while also assuming responsibility for quality assuran
Show less
Read more
Impact Snapshot
Event Time:
RANI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RANI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RANI alerts
High impacting Rani Therapeutics Holdings, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RANI
News
- Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical OfficerGlobeNewswire
- Rani Therapeutics (NASDAQ:RANI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.MarketBeat
- Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGenGlobeNewswire
- Rani Therapeutics (NASDAQ:RANI) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Rani Therapeutics (NASDAQ:RANI) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
RANI
Earnings
- 8/7/25 - Beat
RANI
Analyst Actions
- 1/9/26 - HC Wainwright
RANI
Sec Filings
- 1/30/26 - Form SCHEDULE
- 1/2/26 - Form 8-K
- 12/5/25 - Form DEF
- RANI's page on the SEC website